
Can hospital superbugs chew up stents and implants? Here's what a new study says
The finding means that bacteria, such as the one they studied, could degrade medical implants, lead to infections at the site of the implant and cause infections that are harder to treat.
What did the researchers find?
There are bacteria in the environment that have developed the capacity to break down different types of plastics. So researchers wanted to see whether bacteria that cause infections in humans could also lead to such degradation within the body.
For the study, scientists looked for different pathogens with genes that could potentially produce enzymes similar to the ones that environmental bacteria use to degrade plastics. While they found several hits, they selected a Pseudomonas aeruginosa sample that came from a patient's wound. They isolated an enzyme — which they named Pap1— that could digest a type of bio-degradable plastic frequently used in medical devices called polycaprolactone (PCL) plastic. The researchers found that the enzyme degraded 78 per cent of the plastic sample in just seven days.
Importantly, the researchers found that the bacteria were not only degrading the plastic, they were also using it as their carbon source — effectively eating it. 'This means we need to reconsider how pathogens exist in the hospital environment. Plastics, including plastic surfaces, could potentially be food for these bacteria. Pathogens with this ability could survive for longer in hospitals,' Dr Ronan McCarthy, author and professor of biomedical sciences at Brunel University, said in a release.
Why is this concerning?
This is concerning for several reasons: One, bacteria could live on in hospitals or within a patient even when there aren't any other nutrients present. Two, they could degrade medical devices that use plastics, leading to their failure. This could lead to a rethink of materials that should be used for medical devices. Three, researchers found that the plastic-digesting bacteria could cause more severe infections. The researchers further found that the bacteria were using the broken down plastic molecules to create biofilms (a matrix made of sugars, proteins, fats and DNA) that make pathogens more resistant and difficult to treat. Four, degrading medical devices would also mean that the pathogens would be able to create pits and niches within the human body, where it could be shielded from the immune system and antibiotics, again causing difficult-to-treat infections.
Are there other pathogens that could have this ability?
Researchers found that other pathogens like Streptococcus pneumoniae, Klebsiella pneumoniae and Acinetobacter baumannii, too, carried genes that could potentially create plastic-digesting enzymes. More studies are needed. Importantly, the researchers found that Pap1 enzyme was structurally similar to known enzymes that can degrade even more hardy plastics such as PET bottles.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Hindustan Times
3 days ago
- Hindustan Times
The impact and driving force behind India's National Sickle Cell Anaemia Elimination mission
In just over a year since its launch, India's National Sickle Cell Elimination Mission (NSCEM) is already demonstrating a notable impact in the nation's fight against Sickle Cell Disease (SCD). This public health initiative, active in 278 districts across the country, has rapidly transformed the approach to both diagnosis and management of SCD. With a focus on tribal populations which are more susceptible to the disease and an ambitious target to eliminate SCD as a public health problem by 2047, the mission has achieved unprecedented reach, which is evident in its screening numbers. The initiative aims to eliminate Sickle Cell Disease by 2047. According to government statistics, more than 42 million people were screened for SCD in the first year. This figure, in comparison, is over 10 times the annual number of babies screened in the universal new born screening program in the United States (approximately 3.6 million) and 70 times more. This daily identification rate is roughly equivalent to the total number of new births affected over an entire year in the United Kingdom. Furthermore, approximately 2,500 carriers of the sickle cell trait are identified daily. While these individuals do not present immediate clinical concerns, their identification is critical for future prevention. These carriers are informed about the disease and offered premarital screening and genetic counselling to help prevent the transmission of SCD to future generations. All screened individuals are given a standardised, color-coded identity card that visually indicates their sickle cell status and reproductive risk in an accessible format. The mission's multi-pronged approach extends beyond screening to encompass comprehensive care and counselling and also future research. This includes: Prevention strategies Prevention of serious infections has played a key role in SCD management. Immunisations against Streptococcus pneumoniae and Haemophilus influenzae have improved survival rates and brought down deaths caused by the pneumococcal disease. The government is also carrying out mass screenings and those at high-risk are being counsel Prenatal screening For couples at risk, prenatal screening for SCD using advanced techniques like chorionic villus sampling and amniocentesis, is made available at Government of India's expense. This empowers families to make informed decisions. Efforts are being made to improve access to these services in geographically remote areas also. Social support and legal protection Recognising the challenges faced by individuals with SCD, the Rights of Persons with Disabilities (RPWD) Act of 2016 includes thalassemia, haemophilia, and SCD among the three haematological disorders covered. This act provides vital protections and entitlements for those with 40 per cent or more disability, including: · Accommodations at school and work, such as flexible timings and extra leave to allow for medical care · Relaxation in attendance requirements and additional time for timed examinations · Financial assistance for medical expenses · Consideration for employment opportunities in proximity to comprehensive care facilities The Act also mandates non-discrimination, upholds the right to equality and life with dignity, offers incentives for employers to hire individuals with disabilities, and provides preferences in admission to higher education courses. Advancements in disease-modifying therapies Hydroxyurea: A widely used disease-modifying therapy, Hydroxyurea (HU) has been used in patients with SCD in India since 2008. HU is dispensed free of charge through government health systems and is commercially available at low cost. It is manufactured domestically by several pharmaceutical companies, ensuring ready availability. An oral liquid formulation, stable at room temperature is also being manufactured in India, offering a significant advantage for treating children in remote, tropical regions. HU has proven effective in reducing painful episodes, blood transfusion needs, and hospitalisation rates. It is currently being given to all patients with sickle cell disease starting at two years of age. Research is ongoing to assess the efficacy of different dosages and dose escalation strategies. Advancements in curative therapies Hematopoietic Cell Transplantation: Hematopoietic Cell Transplantation (HCT), often referred to as bone marrow transplant, has been gaining popularity in India over the past four decades. The country now has 114 HCT centres, with 89 reporting results to a bone marrow transplant registry. Clinical research India is emerging as a hub for SCD clinical trials, with approximately 47 trials registered in the Clinical Trial Registry India for SCD. These trials encompass a range of interventions, including HU, haploidentical transplant conditioning regimens, and novel drug candidates pyruvate kinase activator, fetal haemoglobin (HbF) inducers. With large numbers of patients with SCD and medical services in private and academic hospitals, India has the potential to serve as a source for conducting interventional clinical trials. Looking into the future Announced by PM Narendra Modi in 2023, NSCEM is a comprehensive effort to improve the care of all SCD patients and lower disease prevalence. Some of its core pillars include: · Increasing awareness for SCD and pre-marital genetic counselling · Prevention via universal screening and early detection · Providing continuous care across primary, secondary, and tertiary healthcare levels · Strengthening tertiary and quaternary healthcare facilities · Encouraging community adoption and providing support systems The progress of the mission is meticulously tracked and updated in real-time on a public online portal, guiding resource allocation at district, state, and national levels. Furthermore, recognising the potential of transformative therapies, the Government of India has made significant investments in research to develop gene therapies for SCD domestically. While concerns about feasibility and cost in low and middle-income countries remain, India's proactive research support comes as a glimmer of hope for future curative solutions. Note to the Reader: This article has been produced on behalf of the brand by HT Brand Studio and does not have the journalistic/editorial involvement of Hindustan Times. The information provided does not constitute medical advice. Please consult a registered medical practitioner for health-related concerns.


NDTV
4 days ago
- NDTV
Korean Scientists Develop Memory Device That Vanishes In Water
In a major scientific breakthrough, South Korean researchers have developed a biodegradable memory device that dissolves in water. Scientists at the Korea Institute of Science and Technology (KIST) combined strong data storage capabilities and full biodegradability to address the e-waste problem, which has become a big environmental concern in recent years. The new molecular structure is called PCL-TEMPO, which combines TEMPO -- a functional organic molecule capable of storing electrical information-with polycaprolactone (PCL), a biodegradable polymer. This novel design enables both electrical signal storage and natural degradation to be achieved within a single molecular system. "This achievement is technologically significant as it marks the first example of integrating physical self-destruction into a high-performance organic memory device," said Dr Sangho Cho, one of the lead scientists of the project. "In the future, we aim to evolve this into an 'intelligent transient electronic device' by incorporating self-healing and photo-responsive capabilities, accelerating the commercialisation of next-generation bioelectronics and eco-friendly devices," said Dr Sangho. Apart from being environment-friendly, the device successfully retained stored data for more than 10,000 seconds and distinguished between On and Off states over one million cycles. "Moreover, the device showed no degradation after more than 250 write-erase cycles or after being bent over 3,000 times, an exceptional combination of durability and performance for an organic electronic device," the study highlighted. The memory chip can be safely implanted in the human body and is designed to degrade only when needed. The researchers can control the thickness and composition to control when degradation begins. Once the outer layer dissolves, the material vanishes in water in about three days, leaving no residue behind. Plastic that vanishes Earlier this month, Japanese scientists also announced the development of a new type of plastic that dissolves in seawater, potentially offering a breakthrough in dealing with ocean pollution. The researchers revealed that the new material leaves behind nitrogen and phosphorus, which microbes can metabolise and plants can absorb. It is non-toxic for humans, has fire-resistant capabilities and does not release carbon dioxide.


The Print
25-06-2025
- The Print
Lancet report highlights gaps in immunisation—no routine vaccine for 14.4 lakh Indian kids in 2023
The report—published in The Lancet Wednesday—said that in 2023, more than half of the 1.57 crore unvaccinated children worldwide were living in just eight countries, primarily in sub-Saharan Africa (53 percent) and South Asia (13 percent). New Delhi: Nearly 14.4 lakh children in India did not receive a single shot of any routine vaccine in 2023, with the country recording the second-highest 'zero dose' kids, according to a new and significant analysis by the Global Burden of Disease Study Vaccine Coverage Collaborators. The lack of immunisation against deadly diseases puts children at risk of life-threatening diseases, says the World Health Organisation (WHO). 'The challenge now is how to improve vaccine delivery and uptake in areas of low coverage,' said lead author Dr Emily Haeuser. She added that the world would miss the immunisation goals for 2030 without targeted, equitable immunisation strategies, alongside the strengthening of primary healthcare and efforts to tackle vaccine misinformation and hesitancy. The World Health Organisation recommends a range of eleven three-vaccine combinations for all children globally, targeting polio, diphtheria, tetanus, pertussis, measles, mumps, rubella, tuberculosis, hepatitis B, Haemophilus influenzae type b (Hib), Streptococcus pneumoniae, rotavirus, varicella, etc. Vaccine coverage between 1980 and 2023 has globally doubled against diphtheria, tetanus, whooping cough (pertussis), measles, polio, and tuberculosis, according to the report funded by the global vaccine alliance GAVI and The Gates Foundation. Additionally, the number of children who never received a routine childhood vaccine—known as zero-dose children—declined globally by 75 percent between 1980 and 2019. Their number dropped from 5.68 crore to 1.47 crore just before the COVID-19 pandemic. But since 2010, progress has stalled or reversed in many countries, with measles vaccination declining in 100 of 204 countries between 2010 and 2019. In 2023, an estimated 1.57 crore million zero-dose children had not received any doses of the diphtheria, tetanus, and pertussis vaccines in their first year of life, the report pointed out. In India, under the Centre-run Universal Immunisation Programme, vaccines against 12 diseases are offered free of cost to all children, and in some cases, pregnant women at a specified age, via government hospitals. In a rebuttal to a United Nations Children's Fund, which had shown a high number of zero-dose children in India last year, the Union health ministry had said the 'reports depict an incomplete picture of the country's immunisation data as they do not factor in the population base and immunisation coverage of the countries compared'. ThePrint has reached out to Union Health Secretary Punya Salila Srivastava over email for a response to the report. This copy will be updated if and when a reply is received. Independent experts ThePrint spoke with pointed at the disruption in routine immunisation services during the pandemic across health systems that prioritised COVID-19 care mainly. Traditionally, misinformation and vaccine hesitancy among some population groups have constantly remained barriers. 'The number of zero-dose children has been low in some tribal and other religious minority communities due to a reluctance to accept routine vaccines over the fear of serious side effects,' infectious disease specialist Dr Ishwar Gilada said. India now needs to prioritise providing vaccination coverage to such groups, Gilada said, adding that it was paramount that people saw these figures in context, such as considering the population of India. Also Read: Don't scratch mosquito bites. Here is how to deal with itching, redness Countries with a huge vaccination gap India has consistently featured among the countries with the highest numbers of zero-dose children. According to the report, 53·5 percent of zero-dose children lived in five countries—India, China, Indonesia, Pakistan, and Bangladesh—in 1980. By 2019, most of them—52.8 percent of zero-dose children—still lived in only seven countries, which are Nigeria, India, Ethiopia, the Democratic Republic of the Congo, Brazil, Somalia, and Pakistan. The COVID-19 pandemic, which, in many areas, resulted in declining trust in public health institutions and polarised opinions on the necessity, as well as safety, of COVID-19 vaccines, has had varying effects on public perceptions regarding the importance of routine childhood vaccination and willingness to vaccinate, according to the report. Substantial increases in coverage are necessary in many countries and territories, and those in sub-Saharan Africa and South Asia face the toughest challenges, the report noted. (Edited by Madhurita Goswami) Also Read: Eli Lilly announces trial results for world's 2nd weekly insulin, aims for launch by year-end